• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why AbCellera Biologics (ABCL) Is Back In The Spotlight

    Simply Wall St·09/19/2026 18:19:47
    語音播報

    Why AbCellera Biologics Stock Is Back In Focus

    AbCellera Biologics (ABCL) has drawn fresh attention after announcing an upcoming oral presentation of Phase 2 data for its investigational menopause drug ABCL635 at the International Menopause Society congress.

    The treatment targets moderate to severe vasomotor symptoms such as hot flashes, an area with a large patient population and meaningful unmet need, which helps explain why traders are watching the shares ahead of the data update.

    The upcoming ABCL635 data has arrived after a sharp swing in sentiment around AbCellera Biologics, with the shares delivering a 90 day share price return of 128.39% and a year to date share price return of 268.22%, while the 1 year total shareholder return sits at 180.04% and the 5 year total shareholder return remains down 40.28%. This points to strong recent momentum following a tougher longer term journey.

    Scan how traders are pricing similar stories in human health by reviewing the hand picked 37 healthcare AI stocks that echo AbCellera Biologics' push into AI powered drug discovery.

    AbCellera Biologics has already delivered a sharp rebound, yet the business still reports modest revenue and a sizeable loss. Has most of the rerating already played out, or does valuation still leave room for upside?

    Most Popular Narrative: 13.6% Undervalued

    AbCellera Biologics last closed at $12.63, while the most followed narrative tags fair value at $14.63. This frames the recent rebound as only a partial catch up to that estimate rather than a completed move.

    The completion of AbCellera's integrated clinical manufacturing capabilities by the end of 2025 is likely to enhance operational efficiency and reduce COGS, potentially improving net margins as the company begins utilization of these capabilities. Financial backing with over $630 million in liquidity and additional funding commitments provides AbCellera with the necessary resources to support long term pipeline development, enhancing potential future earnings through successful commercialization of their clinical candidates.

    See why 58 investors see AbCellera Biologics as 14% undervalued.

    Result: Fair Value of $14.63 (UNDERVALUED)

    Still, if the ABCL635 menopause program stumbles in later trials or high R&D spend keeps annual losses elevated, AbCellera Biologics' recent rerating could quickly unwind.

    Find out about the key risks to this AbCellera Biologics narrative.

    Next Steps

    Sentiment around AbCellera Biologics is clearly divided, with notable risks on one side and meaningful potential rewards on the other. Review the key concerns and bright spots for yourself by examining the 1 key reward and 3 important warning signs

    Looking for more AbCellera Biologics style ideas?

    If you only stop at AbCellera Biologics, you may miss other opportunities that fit your risk profile and return goals just as well.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.